PDCD1 and acute myeloid leukemia: These findings substantiate the association between high levels of PD-1/PD-L1 at immune checkpoints and poor prognosis in AML, indicating that targeting the PD-1/PD-L1 signaling pathway may represent a promising therapeutic strategy for this malignancy.